NCT05317858 - Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 12, 2022

Primary Completion Date

June 1, 2027

Study Completion Date

December 1, 2027

Conditions

Brain TumorNon Small Cell Lung Cancer

Interventions

DEVICE

Blood Brain Barrier Opening - Oncology

BBB opening via Exablate Type 2 system with microbubble resonators on the day of ICI infusion to treat brain metastases.

DRUG

Pembrolizumab

Pembrolizumab infusion

DRUG

Atezolizumab

Atezolizumab infusion

DRUG

Cemiplimab

Cemiplimab infusion

DRUG

Nivolumab

Nivolumab infusion

DRUG

Iptilimumab

Iptilimumab infusion

Trial Locations (7)

21201

RECRUITING

University of Maryland, Baltimore

23235

RECRUITING

Johnston Willis Hospital, Richmond

33176

RECRUITING

Miami Cancer Institute at Baptist Health, Miami

85013

NOT_YET_RECRUITING

St. Joseph's Hospital and Medical Center, Phoenix

02903

RECRUITING

Rhode Island Hospital, Providence

M4N 3M5

COMPLETED

Sunnybrook Research Institute, Toronto

06351

COMPLETED

Samsung Medical Center, Seoul